Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 32

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 32
---
 correctly estimate our
future operating expenses, which could lead to cash shortfalls.

The estimates of our future
operating and capital expenditures are based upon our current business plan, our current operations and our current expectations
regarding the commercialization of our proprietary formulations. Our projections have varied significantly from actual performance
in the past as a result of changes to our business model, strategy and acquisitions. We may not accurately estimate the potential
revenues and expenses of our operations. If we are unable to correctly estimate the amount of cash necessary to fund our business,
we could spend our available financial resources much faster than we expect. If we do not have sufficient funds to continue to
operate and develop our business, we could be required to seek additional financing earlier than we expect, which may not be
available when needed or at all, or be forced to delay, scale back or eliminate some or all of our proposed operations.

 21 

If we do not successfully identify and acquire
rights to new products and drug candidates and successfully integrate them into our operations, our growth opportunities may be limited.

We plan to pursue the development
of new FDA approved products and drug candidates which may include continued activities to develop and commercialize current assets or,
if and as opportunities arise, potential acquisitions of new intellectual property rights and assets. We have historically relied, and
we expect to continue to rely, primarily upon third parties to provide us with additional development opportunities. We may seek to enter
into acquisition agreements or licensing arrangements to obtain rights to develop new formulations and FDA approved products in the future,
but only if we are able to identify attractive products and formulations and negotiate acquisition or license agreements on terms acceptable
to us, which we may not be able to do. Moreover, we have limited resources to acquire additional potential product development assets
and integrate them into our business. Acquisition opportunities may involve competition among several potential purchasers, which could
include large multi-national pharmaceutical companies and other competitors that have access to greater financial resources than we do.
If we are unable to obtain rights to development and commercial opportunities from third parties and we are unable to rely upon our compounding
pharmacies and current and future relationships with pharmacists, physicians and other inventors to provide us with additional development
opportunities, our growth and prospects could be limited.

Our product development strategy
is to focus on ophthalmology and eye care related products and formulations for which we believe there is broad market potential, large
unmet needs and/or unique value to physicians and patients and to